The Top Stock to Buy With $30 for 2026

Core Viewpoint - Pfizer (NYSE: PFE) is currently trading below $30 per share, presenting a potential investment opportunity despite recent financial challenges [1]. Financial Performance - Pfizer's financial performance has been declining in recent years and is expected to continue this trend through 2028 due to the loss of patent exclusivity for key products, including the anticoagulant Eliquis [3]. - The company anticipates revenue declines in certain years as it navigates these challenges, indicating that it is not yet out of difficult times [3]. Growth Potential - Despite weak revenue and earnings growth projections, Pfizer could see significant share price increases due to advancements in its clinical and regulatory programs over the next three years [4]. - Investors are encouraged to consider initiating positions now, as the potential for upside may diminish if they wait for substantial improvements in financial results [4]. Promising Candidates - Two promising candidates that could significantly impact Pfizer's future are MET-097i, an investigational weight loss medicine with a favorable tolerability profile, and PF-4404, which is being explored for multiple cancer types [5][6]. - The weight loss market is rapidly expanding, making MET-097i a potentially important asset for Pfizer, while PF-4404 could lead to multiple indications, enhancing the company's growth prospects [6].